Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Adcetris meets modified PFS endpoint in Phase III for first-line classical Hodgkin's lymphoma

Seattle Genetics Inc. (NASDAQ:SGEN) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) reported data from the Phase III ECHELON-1 trial in 1,334 patients with stage III or IV classical Hodgkin's lymphoma not previously treated with systemic chemotherapy or radiotherapy showing that Adcetris

Read the full 409 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE